ArticleScientific reports2019
Features of diclofenac biodegradation by Rhodococcus ruber IEGM 346.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Review
- Molecular Monitoring in Soil Bioremediation: From Genetic Potential to Verified Pathway Operation.International journal of molecular sciences · 2026Review
- Enhanced Diclofenac Biodegradation by Bacterial Strains and a Microbial Consortium from Activated Sludge: Toxicity Assessment and Insights into Microbial Community Dynamics.Journal of xenobiotics · 2026Article
- Advanced microbial engineering approaches for biodegradation of pharmaceutical pollutants.Biodegradation · 2025Review
- Elucidating the metabolic pathway and initial degradation gene forApplied and environmental microbiology · 2025Article
- Adaptive responses ofFrontiers in bioengineering and biotechnology · 2025Article
- ResistantMicroorganisms · 2024Article
- Unravelling the role of the group 6 soluble di-iron monooxygenase (SDIMO) SmoABCD in alkane metabolism and chlorinated alkane degradation.Microbial biotechnology · 2024Article
- Editorial: Pharmaceutically active micropollutants - how serious is the problem and is there a microbial way out?Frontiers in microbiology · 2024Article
- Complete Biodegradation of Diclofenac by New Bacterial Strains: Postulated Pathways and Degrading Enzymes.Microorganisms · 2023Article
- Article
- Evaluation of the Defined Bacterial Consortium Efficacy in the Biodegradation of NSAIDs.Molecules (Basel, Switzerland) · 2023Article
- [Research of diclofenac sodium-loaded gelatin scaffold with anti-inflammatory activity for promotingZhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2023Article
- Ketoprofen as an emerging contaminant: occurrence, ecotoxicity and (bio)removal.Frontiers in microbiology · 2023Review
- Diclofenac, ibuprofen, and paracetamol biodegradation: overconsumed non-steroidal anti-inflammatories drugs at COVID-19 pandemic.Frontiers in microbiology · 2023Review
- Phenotypic and metabolic adaptations ofFrontiers in microbiology · 2023Article
- Biosynthesis and Characterization of Gold Nanoparticles Produced UsingInternational journal of molecular sciences · 2022Article
- Characteristics and growth kinetics of biomass of Citrobacter freundii strains PYI-2 and Citrobacter portucalensis strain YPI-2 during the biodegradation of Ibuprofen.International microbiology : the official journal of the Spanish Society for Microbiology · 2022Article
- Cellular Modifications of Rhodococci Exposed to Separate and Combined Effects of Pharmaceutical Pollutants.Microorganisms · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the ability of rhodococci to biodegrade diclofenac (DCF), one of the polycyclic non-steroidal anti-inflammatory drugs (NSAIDs) most frequently detected in the environment. Rhodococcus ruber strain IEGM 346 capable of complete DCF biodegradation (50 µg/L) over 6 days was selected. It is distinguished by the ability to degrade DCF at high (50 mg/L) concentrations unlike other known biodegraders. The DCF decomposition process was accelerated by adding glucose and due to short-term cell adaptation to 5 µg/L DCF. The most typical responses to DCF exposure observed were the changed ζ-potential of bacterial cells; increased cell hydrophobicity and total cell lipid content; multi-cellular conglomerates formed; and the changed surface-to-volume ratio. The obtained findings are considered as mechanisms of rhodococcal adaptation and hence their increased resistance to toxic effects of this pharmaceutical pollutant. The proposed pathways of bacterial DCF metabolisation were described. The data confirming the C-N bond cleavage and aromatic ring opening in the DCF structure were obtained.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.